Autonomix Medical (AMIX) Stock Price

Autonomix Medical Price

NYSE·CLOSED
3.13
​
Market closed

Analysts set a median price target of 6.73 USD, implying 115.1% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Autonomix Medical stock price

Access this data via the Eulerpool API

Autonomix Medical business model & stock analysis

Autonomix Medical Inc is a US-based company operating in industry. The company is headquartered in The Woodlands, Texas and currently employs 3 full-time employees. The company went IPO on 2024-01-29. Autonomix Medical, Inc. is a medical device company, which is focused on advancing technologies to treat diseases involving the peripheral nervous system. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. The company is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.

Frequently asked questions about Autonomix Medical

Analysts currently set an average price target of 6.73 USD for the Autonomix Medical stock (median: 6.73 USD), implying +115.1 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Autonomix Medical stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Autonomix Medical share trades at 2.79 EUR (3.13 USD).

The revenue cannot currently be calculated for Autonomix Medical.

The profit of Autonomix Medical is -16.72 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Autonomix Medical is currently -0.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Autonomix Medical stock.

The P/S cannot be calculated for Autonomix Medical currently.

The Eulerpool Quality Score for Autonomix Medical is 2/10.

The ISIN of Autonomix Medical is US05330T2050. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Autonomix Medical is AMIX. The ticker symbol is used to trade Autonomix Medical shares on the stock exchange.

Fair ValueTerminal
2.91 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 29, 2024
ISIN
US05330T2050
Market capitalization
21.63 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-0.01
P/Ee 2028
-0.01
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
3.67
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-283.55 %
Last updated Oct 9, 2026, 10:43 AM

Autonomix Medical Peer Group